强生公司的研究药物在两项研究中达到了主要目标。 Johnson & Johnson's Investigational Drug Meets Primary Goal In Two Studies.
强生公司的在研药物 nipocalimab 已在患有全身性重症肌无力 (gMG) 和干燥病 (SjD) 的成人患者中证明了临床效果，达到了 3 期 VIVACITY 研究和 2 期 DHLIAS 研究的主要目标。 Johnson & Johnson's investigational drug nipocalimab has demonstrated clinical effects in adults living with generalized myasthenia gravis (gMG) and Sjögren's disease (SjD) meeting the primary goal in the Phase 3 VIVACITY study and Phase 2 DAHLIAS study. GMG 是一种自身抗体驱动的神经肌肉疾病，其特征是波动性肌肉无力，而 SjD 会影响眼睛和其他腺体，导致眼睛和口腔干燥。 GMG is an autoantibody-driven neuromuscular disease characterized by fluctuating muscle weakness, while SjD affects the eyes and other glands, leading to dryness of the eyes and mouth. 尼泊卡利单抗在治疗类风湿性关节炎以及胎儿和新生儿溶血病方面也显示出积极的效果。 Nipocalimab also showed positive results in treating rheumatoid arthritis and hemolytic disease of the fetus and newborn.